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Sa multinational study that assessed the effectiveness of DA using the SilverHawkTM
and TurboHawkTMPlaque ExcisionSystems (Covidien/ev3, Plymouth, MN) for
treatment of peripheral arterial disease.
Methods: The DEFINITIVE LE study enrolled 800 patients. Of those, 70 had CLI
and at least one infrapopliteal target lesion treated with DA. Endpoints and adverse
events were assessed by independent core laboratories and a Clinical Events
Committee. The primary endpoint for the CLI cohort was freedom from major
unplanned amputation of the target limb at 12 months.
Results: Within the DEFINITIVE LE study, 70 patients with CLI had 96 infrapo-
pliteal target lesions treated with DA. The breakdown by Rutherford Clinical Category
(RCC) was as follows: RCC 4: 34%, RCC 5: 63%, and RCC 6: 3%.The mean age
was74 years, 56% were male and79% had diabetes.The mean lesion length was 6.0
cm and the mean baseline stenosis was 77%. One-third (33%) of lesions were
occluded,31% of lesions were calciﬁed and 39% had inﬂow disease treated during the
same procedure.Periprocedural complications included 1 (1%) perforation and 3 (4%)
embolizations; there were no ﬂow-limiting dissections. At 12 months, limb salvage
was 94%, primary patency was 78% and freedom from target lesion revascularization
(TLR) was 87%, per Kaplan-Meier estimates. Complete wound healing at 12 months
was 68%.
Conclusions: This prospective assessment of DA for treatment of Infrapopliteal
lesions in CLI patients showed low complication rates and high rates of limb salva-
ge,freedom from TLR, and primary patency at 12 months comparable to recent drug
eluting stent trials. These ﬁndings should be taken into consideration when treating
this challenging group of patients.
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Background: The natural history of patients with intermittent claudication (IC) has
been reported. However, little is known about prognosis of claudicant patients after
endvascular therapy (EVT).
Methods: This study was performed as a large-scale multicenter, retrospective
registry. A total of 2,930 consecutive patients (mean age, 71.58.9 years, 78.7%
male) with IC treated by EVT for a de novo ilio-femoral lesion were enrolled. The
primary outcome measure was overall survival, and the secondary outcome measure
were freedom from major adverse cardiovascular events (MACE; all-cause death
(ACD), myocardial infarction and stroke), and major adverse cardiovascular and limb
events (MACLE; any repeat revascularization for limb and leg amputation in addition
to MACE).
Results: The overall survival rate was 97.2%, 90.8%, and 83.4% at 1, 3 and 5 years.
The cause of death was cardiovascular in 42.8%. Freedom from MACE (MACLE)
was 96.7% (84.5%), 88.6% (68.1%), and 77.3% (58.7%) at 1, 3and 5 years. On
multivariate analysis performed logistic regression by prespeciﬁed risk factors,
elderly age, Dialysis, LV dysfunction, Insulin administration, complication of
hematoma, Coronary artery disease, SFA plus iliac lesions were found to be positive
independent predictors of ACD. ACEI/ARB, Ca-antagonist administration were
negative predictor. Risk stratiﬁcation of ACD based on these seven positive
predictors. Elderly age, Dialysis, LV dysfunction, Insulin administration and
complication of hematoma were scored as 2 points. The others were assigned 1 point
each. The scores of 0 to 2, 3 to 5, and >6 points were classiﬁed as low-, moderate-
and high-risk patients, respectively. The overall survival rate was signiﬁcantly lower
in the high-risk patients than other two groups (90.1% vs. 78.6% vs. 53.5% at 5years,
P<0.0001; log-rank test).
Conclusions: The prognosis after EVT for patients with IC was relative good.
However, that for high risk patients with IC was extremely poor.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrInvasive Imaging
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Background: The EGO-COMBO study is the ﬁrst study ever designed to establish
the healing proﬁle of a DES, and beneﬁts of the dual therapy COMBO Stent
(OrbusNeich, US), a hybrid version of the EPC-capturing Genous Stent plus a 5mg/
mm abluminal sirolimus coating, using sequential OCT FUs to 24 months.
Methods: In this prospective single center study, 61 patients (9M DAPT) received 3
longitudinal sequential OCTs at baseline (for optimal stent apposition), at early FU (4
monthly group 2nd to 5th month, in 1:2:2:1 ratio, for % strut coverage using 6
Categories), then at 9M (for late loss and OCT neointima), and clinical FU to 12M.
With a 2nd approved protocol, a 24M OCT FU was initiated for long term outcomes.
All clinical event adjudication, QCA & OCT analyses were undertaken by CRF Core
Lab., NY.
Results: 61 patients (33% DM) received 88 COMBO stents (size 3.060.39mm &
length 23.97.62mm). Early strut coverage (OCT Cat. D to F) increased from 84.3,
90.2, 90.5, to 92%; interpolated 100% coverage at 150 days. 9M OCT FU Rate was
100%; only 1 TLR treated by POBA (MACE Rate 1/61 ¼ 1.64%). 9M late loss was
0.240.36mm, OCT NIT 0.157mm & NIA 1.445mm2. At 24M, 1 case lost to FU
(migrated to China), another elderly patient died from VF after days of recurrent chest
pain without seeking advice. All remaining 59 cases were entirely asymptomatic & 18
declined the 4th OCT FU (24M Clinical FU Rate 58/59 ¼ 98.3% & OCT FU Rate 40/
58 ¼ 69.0%). To date, 39 patients have had the restudy, all showing excellent results
(late loss catch up <0.1mm; OCT NIT D 0.002mm; NIA D 0.13mm2), without
neoatherosclerosis or late stent thrombosis (not even micro-thrombi by OCT). Thus,
24M MACE Rate 2/61 ¼ 3.28%; ﬁnal core lab. results pending.
Conclusions: Using stringent longitudinal sequential OCT FUs with core lab. adju-
dication, the dual therapy COMBO stent is the ﬁrst DES ever with a healing proﬁle
established and appears to be a novel device (excellent healing with optimal neo-
intimal suppression without late stent thrombosis) with durable 24M outcomes. This
longitudinal sequential OCT FU approach may be adopted to guide development of
any new stent platform, appropriate DAPT duration, and to predict (prevent) late stent
thrombosis.
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Background: Whether IVUS guidance reduces the long-term rates of stent throm-
bosis (ST) after drug-eluting stent (DES) implantation is controversial.acts/ORAL/Invasive Imaging B21





SMethods: ADAPT-DES was a prospective, multicenter, real-world registry of 8,583
pts at 11 international centers undergoing percutaneous coronary intervention (PCI)
with DES designed to determine the frequency, timing, and correlates (clinical,
angiographic and platelet reactivity) of early and late ST. In a pre-speciﬁed IVUS
substudy, outcomes were examined according to IVUS vs. angiographic guidance. We
herein report the 2-year clinical results.
Results: Average pt age was 64.0 years, and 74.1% were male. During the index
procedure, IVUS guidance was used in 3,361 (39.2%) of procedures. Pts in the IVUS-
guided group were more likely to present with an acute coronary syndrome and have
higher platelet reactivity on clopidogrel (PRU>208), and were treated with longer and
larger stents. At 2-year follow-up, deﬁnite/probable ST occurred in 22 (0.7%) pts in
the IVUS-guidance group vs 71 (1.4%) pts in the angiography-guidance group
(P¼0.002; Table). In a propensity adjusted multivariable model, IVUS guidance was
independently associated with a reduced 2-year rate of ST (HR [95%CI] ¼ 0.43 [0.25,
0.74], p¼0.002), myocardial infarction (MI; 0.65 [0.51, 0.83], p¼0.0006), clinically
driven target lesion target revascularization (TLR; 0.77 [0.62, 0.96], p¼0.02) and
target vessel revascularization (TVR; 0.83 [0.70, 0.97], p¼0.02), and all-cause death/








0.7% (22) 1.5% (71) 0.002
- Early (<30 days) 0.3% (9) 0.6% (30) 0.04
- Late (31 days - 1
year)
0.3% (10) 0.5% (24) 0.24
- Very late (1 year –
2 year)
0.15% (3) 0.45% (19) 0.01
All-cause death 3.3% (106) 4.2% (210) 0.03
Cardiac death 1.7% (54) 2.4% (119) 0.03
Myocardial
infarction
3.5% (112) 5.6% (279) <0.0001
- Peri-procedural 1.3% (44) 1.6% (84) 0.26
- Spontaneous 1.7% (52) 3.1% (151) <0.0001
- Spontaneous (<1
year)
0.8% (27) 1.7% (83) 0.001
- Spontaneous (1
year-2 year)
0.8% (25) 1.5% (68) 0.01
All-cause death/MI 6.3% (203) 9.0% (453) <0.0001
Clinically driven
TLR
4.8% (161) 6.0% (314) 0.02
Clinically driven
TVR
8.3% (279) 9.8% (510) 0.02Conclusions: These data, drawn from the largest prospective study of IVUS-guided
DES implantation to date, strongly suggest that IVUS guidance may result in
improved clinical outcomes after DES, with reduced 2-year rates of ST, TLR and
TVR, and death/MI.
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Background: The current study compared the novel Biotronik Osiro stent, eluting
sirolimus from a biodegradable polymer PLLA, applied to the surface of a thin-strut
(60 mm) Silicon-Carbide coated Cobalt-Chromium stent with the Abbot Xience
Prime stent. The aim was to compare the neointimal hyperplasia, stent appositionB22 JACC Vol 62/18/Suppl B j Ocand stent strut coverage at 9 months after procedure using IVUS and OCT imaging
techniques.
Methods: We performed a prospective, multicenter, randomized controlled study
(RCT) in 452 subjects (63.410.0 yrs) with symptomatic coronary artery disease due
to de novo stenotic lesions in native coronary arteries with a reference vessel diameter
 2.25 mm and  4.0 mm and a lesion length  26 mm. The study is registered at
clinicaltrials.gov (NCT01356888). Subjects were randomly assigned (2:1) to receive
the Osiro SES or the Xience Prime EES. In pre-speciﬁed cohort sizes, the enrolled
subjects were invited to participate in either the IVUS (N¼66) or the OCT (N¼65) sub
studies. All subjects were enrolled between July 5, 2011 - Jan 10, 2012. The IVUS
endpoints were neointimal hyperplasia and stent apposition at 9 months after proce-
dure. The OCT endpoints were neointimal hyperplasia, stent apposition and stent strut
coverage at 9 months. Baseline and 9 month follow-up images were analyzed by
independent and blinded core laboratories; IVUS by Medstar, US and OCT by Car-
dialysis, NL.
Results: IVUS and OCT conﬁrmed complete and a non-signiﬁcant difference in
apposition in both cohorts (OCT P¼0.624 and IVUS P¼0.325). IVUS and OCT
conﬁrmed less neointimal hyperplasia area at 9-months in the Osiro cohort (OCT
P¼0.024 and IVUS P¼0.043). The Osiro cohort had a higher strut coverage and lower
strut-neointima thickness at 9 months, conﬁrmed by OCT (coverage P¼0.042 and
thickness P<0.001).
Conclusions: In this RCT, the Osiro SES with a biodegradable polymer showed
comparable stent and strut apposition to the Xience Prime EES with a durable
polymer. The Osiro had a statistically signiﬁcant lower neointimal area in both the
IVUS and OCT sub studies. OCT analysis of the strut level conﬁrmed that both the
neointima thickness and percent coverage was signiﬁcantly better in the Osiro cohort.
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Background: The objective of this study is to examine the phenotypic changes of the
superﬁcial plaque occurring follow an Absorb bioresorbable vascular scaffold (Absorb
BVS) implantation.
Methods: Forty six patients (47 lesions) who underwent Absorb BVS implantation
and had serial optical coherence tomographic evaluation at baseline, and at any
follow-up time point (6 months, 1 year, 2 years or 3 years) were included in the
current analysis. Two observers identiﬁed thin capped ﬁbroatheromas (TCFA) in the
scaffolded and native segments that were located proximally or distally to the scaf-
folded segment, marked the circumferential location of the TCFA and of the calciﬁc
tissues and measured the thickness of the developed neointima at follow-up. These
data were used to construct spread-out vessel plots that portrayed the spatial location
of the detected tissues and their extent was expressed as percentage of the endoluminal
vessel wall surface.
Results: Twelve TCFA were detected at baseline in the scaffolded segments and all
were covered at follow-up. On the other hand most of the TCFA identiﬁed in native
segments (6 out of 10) did not change their phenotype at follow-up. The amount of the
superﬁcial lipid core remained unchanged at follow-up in the spread-out vessel plots
in both the scaffolded (4.9010.12% at baseline vs. 4.1810.84%, at follow-up,
P¼0.388) and native segments (28.4720.87% at baseline vs. 28.1222.00%, at
follow-up, P¼0.767). There was no difference in the thickness of the neointima
developed over TCFA and calciﬁc spots in scaffolded segments at follow-up (mean
thickness over TCFA: 22383mm vs. 21388mm over calciﬁc spots, P¼0.687).
Conclusions: Our results demonstrate that the neointimal tissue developed after
Absorb BVS implantation shields equally both lipid and calciﬁc tissues. Thus, the
Absorb BVS could be considered as a potential useful device for the invasive re-
capping of high risk plaques.
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Background: The morphological assessment of neointimal tissue using optical
coherence tomography (OCT) is highly signiﬁcant to clarify the pathophysiology of
in-stent restenosis (ISR) lesions. These OCT ﬁndings may be related to recurrence of
ISR. The aim of this study was to deﬁne the impact of OCT ﬁndings on recurrence
of ISR after various types of percutaneous coronary intervention (PCI) including plaintober 27–November 1, 2013 j TCT Abstracts/ORAL/Invasive Imaging
